Targets and inhibits proteasome activity, causing disruption of normal homeostatic mechanisms and leading to cell death.

Given as 1.3 mg/m² per dose.

IV bolus administered twice weekly for two weeks followed by 10-day rest period.

Indicated for patients with multiple myeloma who have received at least one prior therapy and patients with mantle cell lymphoma who have received at least one prior therapy.

Myelosuppression, nausea, vomiting, diarrhea, constipation, anorexia, dose-limiting peripheral neuropathy, hepatic and renal toxicity, rash, orthostatic hypotension, flu-like symptoms, fever, and fatigue.

Administer reconstituted agent within eight hours of preparation; use within three hours of preparation if stored in a syringe.

Use caution in patients who are taking antihypertensives.

Thrombocytopenia occurs in approximately 40% of patients, peaking around day 11. CBC should be monitored throughout therapy.

Peripheral neuropathy reported is predominantly sensory, although some cases of sensory-motor peripheral neuropathy have been reported.

Administered by a 3-5 second bolus intravenous injection into a peripheral line or into an infusion port.

Contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol.